NOT AN OFFER TO INVEST. RED HERRING DISCLOSURE AVAILABLE ON REQUEST. PROFESSIONAL INVESTORS ONLY.

WHO Report. In the past 20 years, 870 cases of human infection with the avian influenza H5N1 virus have been reported in 21 countries. Of these cases, 457 were fatal, representing a alarming case fatality rate (CFR) of 52.5% meaning about 1 out of 2 reported infections resulted in DEATH.

Cumulative number of confirmed human cases for avian influenza A(H5N1) reported to WHO, 2003-2023, 5 January 2023

Overview

WHO publishes information on human cases with influenza A(H5N1) avian influenza infection on a monthly basis on the Influenza webpage:

Cases of human infection with A(H5N1) will only be reported on Disease Outbreak News for events that are unusual or associated with potential increased risks.

Member States will be continued to require to report information on every sporadic case of H5N1 human infection or novel influenza virus infection to WHO as per Article 6 of the International Health Regulations (2005).

DOWNLOAD REPORT

2023-02-02T05:09:59+00:00
Forward Looking Statements. No Offer or Solicitation. Professional Investors Only.2023-02-03T11:00:00+00:00

This website includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as “forecast,” “intend,” “seek,” “target,” “anticipate,” “believe,” “will,” “expect,” “estimate,” “plan,” “outlook,” and “project” and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Such forward-looking statements include statements about our beliefs and expectations and the estimated financial information and other projections contained herein. Such forward-looking statements with respect to revenues, earnings, performance, strategies, prospects and other aspects of the businesses of Normax Biomed Ltd. are based on current expectations that are subject to risks and uncertainties. A number of factors could cause actual results or outcomes to differ materially from those expressed or implied by such forward-looking statements. Please refer to the final prospectus of Normax Biomed Limited under “Risk Factors” therein, and other documents filed or to be filed with the London Stock Exchange and the Swiss Stock Exchange (SIX) by Normax Biomed Ltd. You are cautioned not to place undue reliance upon any forward-looking statements, which speak only as of the date made. Normax Biomed Ltd. undertakes no commitment to update or revise the forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

The information on this website shall not constitute a solicitation of a proxy, consent or authorization with respect to any securities or in respect of the proposed transaction. The information on this website shall also not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any states or jurisdictions in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the listing requirements of the London Stock Exchange and the Swiss Stock Exchange (SIX).

This website is directed only at, and provides information about products and services only available to, those who are Professional Clients or Eligible Counterparties as defined by the Financial Conduct Authority. The definitions can be found on the FCA website at www.fca.org.uk. This website is not intended to be accessed by any persons or entities domiciled in any jurisdiction where being treated as the types of clients stated would be contrary to local law.

Normax Abstract2022-08-31T11:50:39+00:00

Normax Biomed Ltd (Normax) is based in Cork, Ireland, and London, England. Normax is in the business of mRNA vaccine Research, Development and Manufacturing. Normax has secured a €300,000,000 capital commitment from a $3.4Bn cornerstone institutional investor for development of mRNA Vaccines and Vax Factory Manufacturing for Transformative Social Impact on Infectious Disease and Pandemic Preparedness. Normax plans to drive down the cost of mRNA Vaccines to save more lives and to deliver sustainable returns for impact investors. Normax plans to deliver safe and effective mRNA vaccines at large scale for about $4 dollars per dose. Normax mRNA vaccine products in development include: (1) mRNA Vax Factory, (2) Universal Coronavirus mRNA Vaccine, (3) Tuberculosis mRNA Vaccine, (4) HIV mRNA Vaccine, (5) Malaria mRNA Vaccine, and (6) Disease-X mRNA Vaccine (e.g. within 100 days). Normax mission is to deliver competitive financial performance with transformative social impact. NOT AN OFFER TO INVEST.

Copyright 2021 | Normax Biomed Limited | First Floor, Penrose 1, Penrose Dock, Cork, Ireland | T23 KW81 | Company Number 669518

Go to Top